Clarity Pharmaceuticals (ASX:CU6) Change In Inventory: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
36 GF Score
Price A$2.45
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Change In Inventory?

Clarity Pharmaceuticals ASX:CU6 +2.08% 36 Change In Inventory is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2025 was A$0.00 Mil. It means Clarity Pharmaceuticals's inventory stayed the same from Jun. 2025 to Dec. 2025 .

Clarity Pharmaceuticals's change in inventory for the fiscal year that ended in Jun. 2025 was A$0.00 Mil. It means Clarity Pharmaceuticals's inventory stayed the same from Jun. 2024 to Jun. 2025 .

Clarity Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Clarity Pharmaceuticals  (ASX:CU6) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clarity Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 2
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Clarity Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Clarity Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Change In Inventory Related Terms

Clarity Pharmaceuticals Change In Inventory Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Change In Inventory Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Change In Inventory
0.00 0.00 0.00 0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CU6
36GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of A$0.00 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Change In Inventory of A$0.00 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Change In Inventory too high?
Clarity Pharmaceuticals' current Change In Inventory is A$0.00 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Change In Inventory compare to VRTX and REGN?
Clarity Pharmaceuticals' Change In Inventory of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Change In Inventory is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Change In Inventory of A$0.00 Mil. The current Change In Inventory is A$0.00 Mil. Clarity Pharmaceuticals' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Change In Inventory is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
36GF Score

Get the complete analysis for ASX:CU6

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.45
Price